INSIGHTS ON CLINICAL TRIAL DESIGN
-
Developing And Validating Clinical Receptor Occupancy Pharmacodynamic Biomarker Assays
Receptor occupancy (RO) assays assess drug-target engagement and support PK/PD modeling. Accurate RO requires customized assays using stabilized blood to monitor CD6 modulation in autoimmune therapy.
-
Medical Insight's Role In Early-Phase Clinical Development
Medical insight reduces risk, strengthens protocols, and accelerates timelines — enhancing safety, feasibility, and collaboration for successful trials and reliable outcomes.
-
Making Early Decisions In Psychiatric Drug Development
Quantitative PD measures provide objective evidence of target engagement, support dose selection, strengthen early go/no-go decisions, and help reduce development risk in psychiatric
-
The Next Frontier In Early Phase Oncology Trials
This session explores the pivotal role of First-in-Human and early phase oncology trials in drug development, emphasizing the importance of comprehensive planning for successful execution.
-
Mastering Scope 3 Emissions In Clinical Trials10/23/2024
Explore innovative strategies for reducing Scope 3 emissions in clinical trials. Discover sustainable solutions that uphold quality and outcomes, crucial for achieving net-zero goals in healthcare research.
-
Challenges And New Approaches To Developing Clinical Evidence For Medical Devices9/12/2024
Learn about the challenges and new approaches to developing clinical evidence for medical devices, including decentralized trials, adaptive studies, in silico trials, and real-world evidence.
-
The Future Of Patient Experience: Lessons From GLP-1 Studies7/29/2026
Improve adherence, retention, and data quality in GLP-1 and cardiometabolic trials through connected digital tools, real-time symptom tracking, caregiver support, and AI-assisted review.
-
Early Immune Profiling With In Vivo, In Vitro, And Ex Vivo Systems10/7/2025
Modern biologics increasingly interact with the immune system. While these innovations enable transformative therapies, they can also provoke acute immune activation during first-in-human (FIH) trials.
-
No More Back And Forth: Building eCOAs Right The First Time5/27/2025
Clinical trial system builds have long been plagued by inefficiencies, miscommunications, and long timelines. Learn about a platform helping sponsors and CRO's overcome these challenges.
CLINICAL TRIAL DESIGN SOLUTIONS
-
Discover Scout's strategies for elevated, eco-friendly face-to-face and hybrid events. ecoScout for Meetings takes a comprehensive approach to minimizing carbon emissions and maintaining the highest standards of quality and service.
-
Psychiatric trials have long been among the most difficult to enroll. From treatment-resistant depression (TRD) and PTSD to cognitive and neuro disorders, sponsors are facing the same challenges over and over again:
- Narrow I/E criteria that don’t translate into real-world patients
- Sites with limited behavioral health infrastructure
- Lack of patient trust and trial awareness in psychiatric populations
- Professional patients
- Rating scales aren’t used in clinical practices
But what if recruitment didn’t have to start with a gamble?
-
Traditional clinical trial models can create financial burden by neglecting participant needs – but effective use of stipends can allow participants to fully engage without financial worries.
-
Looking to better understand how to solve your organization’s specific clinical trial challenges? In 3 minutes, receive a personalized assessment, with customized results based on a specific role, which will provide a solution-based report curated to your priorities and requirements.
-
Second, only to Oncology, CNS, and Neurology clinical trials are incredibly complex and complicated to navigate.